AbSci
AbSci is an e. Coli expression system for protein production founded in 2011 by Sean McClain.
10
Funding Rounds
$437.9m
Money raised
| Name | Phone | Social networks | |
|---|---|---|---|
| Se** Mc***** | - | - |
Funding
Funding series
Funding Series Analysis
The company AbSci has raised a total of $215.4m in funding over 10 rounds.
Key Insights:
- AbSci Initial public offering (IPO): $200m
- AbSci Series D round, January 2020: $15.4m
- AbSci Corp funding round, October 2020: $65m
- AbSci Venture round, March 2021: $125m
- AbSci Venture round, December 2019: $5m
- AbSci Series D round, January 2019: $10.4m
- AbSci Series A round, February 2016: $5.1m
- AbSci Series C round, May 2018: $12m
AbSci Initial public offering (IPO)
$200m
AbSci Series D round, January 2020
$15.4m
AbSci Corp funding round, October 2020
$65m
AbSci Venture round, March 2021
$125m
AbSci Venture round, December 2019
$5m
AbSci Series D round, January 2019
$10.4m
AbSci Series A round, February 2016
$5.1m
AbSci Series C round, May 2018
$12m
Industries
AbSci is active in the following industries:
- Biomedical engineering
- Engineering
- Technology
- Synthetic biology
- Biology
- Biotechnology
- Artificial Intelligence (AI)
- Drug development